Cefixime in the treatment of enteric fever in children

N. I. Girgis, M. E. Kilpatrick, Z. Farid, Y. Sultan, John Podgore

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Cefixime in a dose 20 mg/kg/day, orally, divided into two doses 12 h apart for a minimum of 12 days, was administered to 50 children with proven S. typhi septicaemia. Forty four of the patients were infected with strains of S. typhi resistant to multiple antibiotics including chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. All patients responded rapidly to treatment and were cured clinically and bacteriologically. Fever subsided within a mean of 5.3 days (range 3-8 days). Only two of the 50 patients treated relapsed during the 8 week follow-up period. No serious adverse reactions attributable to the drug were observed. Cefixime proved to be an effective oral drug in this open treatment trial and was associated with minimal side effects. It may provide a therapeutic alternative to the treatment of Salmonella infection with organisms multi-resistant to the standard drug regimens. Its oral formulation may provide an efficient alternative to parenteral therapy in less severely ill patients who can tolerate oral feeding.

Original languageEnglish
Pages (from-to)47-49
Number of pages3
JournalDrugs under Experimental and Clinical Research
Volume19
Issue number1
StatePublished - 1 Jan 1993

Fingerprint

Cefixime
Typhoid Fever
Pharmaceutical Preparations
Therapeutics
Salmonella Infections
Sulfamethoxazole Drug Combination Trimethoprim
Chloramphenicol
Ampicillin
Sepsis
Fever
Anti-Bacterial Agents

Cite this

Girgis, N. I., Kilpatrick, M. E., Farid, Z., Sultan, Y., & Podgore, J. (1993). Cefixime in the treatment of enteric fever in children. Drugs under Experimental and Clinical Research, 19(1), 47-49.
Girgis, N. I. ; Kilpatrick, M. E. ; Farid, Z. ; Sultan, Y. ; Podgore, John. / Cefixime in the treatment of enteric fever in children. In: Drugs under Experimental and Clinical Research. 1993 ; Vol. 19, No. 1. pp. 47-49.
@article{afeb0b3a25354303809c49075559fa43,
title = "Cefixime in the treatment of enteric fever in children",
abstract = "Cefixime in a dose 20 mg/kg/day, orally, divided into two doses 12 h apart for a minimum of 12 days, was administered to 50 children with proven S. typhi septicaemia. Forty four of the patients were infected with strains of S. typhi resistant to multiple antibiotics including chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. All patients responded rapidly to treatment and were cured clinically and bacteriologically. Fever subsided within a mean of 5.3 days (range 3-8 days). Only two of the 50 patients treated relapsed during the 8 week follow-up period. No serious adverse reactions attributable to the drug were observed. Cefixime proved to be an effective oral drug in this open treatment trial and was associated with minimal side effects. It may provide a therapeutic alternative to the treatment of Salmonella infection with organisms multi-resistant to the standard drug regimens. Its oral formulation may provide an efficient alternative to parenteral therapy in less severely ill patients who can tolerate oral feeding.",
author = "Girgis, {N. I.} and Kilpatrick, {M. E.} and Z. Farid and Y. Sultan and John Podgore",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "47--49",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "1",

}

Girgis, NI, Kilpatrick, ME, Farid, Z, Sultan, Y & Podgore, J 1993, 'Cefixime in the treatment of enteric fever in children', Drugs under Experimental and Clinical Research, vol. 19, no. 1, pp. 47-49.

Cefixime in the treatment of enteric fever in children. / Girgis, N. I.; Kilpatrick, M. E.; Farid, Z.; Sultan, Y.; Podgore, John.

In: Drugs under Experimental and Clinical Research, Vol. 19, No. 1, 01.01.1993, p. 47-49.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cefixime in the treatment of enteric fever in children

AU - Girgis, N. I.

AU - Kilpatrick, M. E.

AU - Farid, Z.

AU - Sultan, Y.

AU - Podgore, John

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Cefixime in a dose 20 mg/kg/day, orally, divided into two doses 12 h apart for a minimum of 12 days, was administered to 50 children with proven S. typhi septicaemia. Forty four of the patients were infected with strains of S. typhi resistant to multiple antibiotics including chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. All patients responded rapidly to treatment and were cured clinically and bacteriologically. Fever subsided within a mean of 5.3 days (range 3-8 days). Only two of the 50 patients treated relapsed during the 8 week follow-up period. No serious adverse reactions attributable to the drug were observed. Cefixime proved to be an effective oral drug in this open treatment trial and was associated with minimal side effects. It may provide a therapeutic alternative to the treatment of Salmonella infection with organisms multi-resistant to the standard drug regimens. Its oral formulation may provide an efficient alternative to parenteral therapy in less severely ill patients who can tolerate oral feeding.

AB - Cefixime in a dose 20 mg/kg/day, orally, divided into two doses 12 h apart for a minimum of 12 days, was administered to 50 children with proven S. typhi septicaemia. Forty four of the patients were infected with strains of S. typhi resistant to multiple antibiotics including chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole. All patients responded rapidly to treatment and were cured clinically and bacteriologically. Fever subsided within a mean of 5.3 days (range 3-8 days). Only two of the 50 patients treated relapsed during the 8 week follow-up period. No serious adverse reactions attributable to the drug were observed. Cefixime proved to be an effective oral drug in this open treatment trial and was associated with minimal side effects. It may provide a therapeutic alternative to the treatment of Salmonella infection with organisms multi-resistant to the standard drug regimens. Its oral formulation may provide an efficient alternative to parenteral therapy in less severely ill patients who can tolerate oral feeding.

UR - http://www.scopus.com/inward/record.url?scp=0027434903&partnerID=8YFLogxK

M3 - Article

C2 - 8223140

AN - SCOPUS:0027434903

VL - 19

SP - 47

EP - 49

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 1

ER -